Economic Evaluation of ASA 100mg, Simvastatin 40mg and Ramipril 5-10mg (POLYPILL) for Secondary Prevention of Cardiovascular Events in Mexico

Abstract

A 3 4 7 -A 7 6 6 were taken into account, together with resulting costs and (dis)utilities. Results were specified for subgroups in scenario analyses: NVAF + VTE patients (base case); NVAF and VTE patients separately; unstable NVAF patients with TTR (time in therapeutic range) < 60%. A probabilistic sensitivity analysis (PSA) was performed to investigate the influence of parameter uncertainty on the incremental cost-effectiveness ratio (ICER). Results: For the analyzed subgroups the use of rivaroxaban was cost saving and provided health gains compared to treatment with VKAs. Cost savings were highest for VTE patients, followed by unstable NVAF patients. Health gains were approximately the same for each subgroup at 0.023-0.026 quality adjusted life-years (QALY) per patient. ConClusions: From a healthcare payers perspective in the Dutch setting, rivaroxaban treatment is likely to be dominant over current standard therapy with VKAs, for the prevention of stroke in patients with (unstable) NVAF and treatment of (r)VTE.

Adherencia farmacológica y prevención secundaria cardiovascular: una de las principales barreras en el tratamiento de la enfermedad ateroesclerótica. Posición del Departamento de Prevención Cardiovascular de SOCHICAR en el uso de la polipíldora en prevención secundaria

“…En ambos estudios, el análisis económico mostró que la estrategia de la polipíldora era más efectiva y a menor costo que terapia convencional, tanto en el costo incremental por años de vida como por AVAC ganados. Otros datos vienen de México 62 . A comienzos del 2016 la polipíldora fue incluida en el cuadro básico de prestaciones del sistema de salud en ese país.…”